Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cumberland Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01334957
First received: April 12, 2011
Last updated: April 18, 2016
Last verified: April 2016
Results First Received: April 15, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Pain
Intervention: Drug: Intravenous ibuprofen

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Adult hospitalized patients undergoing surgery

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Patients who met all the inclusion and none of the exclusion criteria during the Screening /Baseline Period were enrolled into the study.

Subjects could not have a history of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin (or aspirin related products) or NSAIDS.


Reporting Groups
  Description
Intravenous Ibuprofen

Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period. A minimum of one dose of intravenous ibuprofen will be administered. At the discretion of the investigator, up to three additional doses of 800 mg intravenous ibuprofen may be administered at six hour intervals.

Intravenous ibuprofen: 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes


Participant Flow:   Overall Study
    Intravenous Ibuprofen
STARTED   300 
Received Single Dose   252 
Received Multiple Doses   48 
COMPLETED   300 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Formal sample size calculations were not performed. The intent is to enroll 300 patients to provide descriptive safety and efficacy data.

Reporting Groups
  Description
Intravenous Ibuprofen

Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.

Intravenous ibuprofen: 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes


Baseline Measures
   Intravenous Ibuprofen 
Overall Participants Analyzed 
[Units: Participants]
 300 
Age, Customized [1] 
[Units: Years]
 
Greater than or equal to 18 years of age   300 
[1] Greater than or equal to 18 years of age
Gender 
[Units: Participants]
 
Female   189 
Male   111 
Ethnicity (NIH/OMB) 
[Units: Participants]
 
Hispanic or Latino   29 
Not Hispanic or Latino   271 
Unknown or Not Reported   0 
Race (NIH/OMB) 
[Units: Participants]
 
American Indian or Alaska Native   1 
Asian   5 
Native Hawaiian or Other Pacific Islander   0 
Black or African American   60 
White   229 
More than one race   0 
Unknown or Not Reported   5 
Region of Enrollment 
[Units: Participants]
 
United States   300 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.   [ Time Frame: 6 hours ]

2.  Primary:   To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.   [ Time Frame: 6 hours ]

3.  Secondary:   To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.   [ Time Frame: 6 hours ]

4.  Secondary:   To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.   [ Time Frame: 6 hours ]

5.  Secondary:   To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Reduction of Post-operative Pain.   [ Time Frame: 6 hours ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Amy Rock
Organization: Cumberland Pharmaceuticals Inc.
phone: 615-255-0068
e-mail: arock@cumberlandpharma.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Cumberland Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01334957     History of Changes
Other Study ID Numbers: CPI-CL-016
Study First Received: April 12, 2011
Results First Received: April 15, 2014
Last Updated: April 18, 2016
Health Authority: United States: Food and Drug Administration